2nd Quarter - Report

THE LIAISON GROUP, LLC for NATIONAL CANNABIS ROUNDTABLE

Firm
Client
Income
$65,500
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Banking BAN

Ensuring cannabis businesses have access to financial services (Congresses the SAFE Banking Ac HR 2891, S. 1323). discussion of broad access to financial institutions

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1323 (118th), H.R. 2891 (118th)

Government Issues GOV

Allowing District of Columbia to have autonomy on issues of creating a regulated cannabis marketplace

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

Working on appropriations provisions that prevent the Department of Justice from interfering in state legal cannabis programs (both medical and adult use), allowing JAG Bryne funding to be used for expungements, banking language, various language proposals allowing veterans to access cannabis, fairness in federal drug testing, language protecting tribal sovereignty on cannabis decisions, and language promoting further research into cannabis.

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Law Enforcement/Crime/Criminal Justice LAW

Bills to reduce criminal penalties of cannabis possession and distribution, including but not limited to for bills that remove cannabis from the Schedules in the Controlled Substances Act. Also active on provisions that would facilitate expungements of cannabis offenses including what was the Misdemeanor Expungement Act last congress and the HOPE Act from last congress.

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES

Consumer Issues/Safety/Products CSP

Engaging with Congress on issues surrounding packaging, labeling, and tracing of regulated cannabis products. Educating on difference between cannabis, synthetic substances, and hemp-derived intoxicating products

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE New Charlie Rangel March 2016- December 2016

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.